Chardan Capital Maintains Sell on Mesoblast, Lowers Price Target to $1.5
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has maintained a 'Sell' rating on Mesoblast (NASDAQ:MESO) and lowered the price target from $2 to $1.5.
August 04, 2023 | 3:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chardan Capital has maintained a 'Sell' rating on Mesoblast and lowered the price target from $2 to $1.5.
The 'Sell' rating maintained by Chardan Capital indicates a negative outlook for Mesoblast. The lowering of the price target from $2 to $1.5 suggests that the analyst believes the stock is overvalued at its current price, which could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100